GlassScriptPhysician profile
Theodore J Paradowski
NPI 1720171804
$5,661.61
in general payments reported to CMS, 2019-2025
18 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $423 · 2021: $456 · 2022: $1,246 · 2023: $405 · 2024: $1,041 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.74 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,556.59 | 2019-2025 | |
| Madrigal Pharmaceuticals | $1,200.97 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $472.05 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $469.85 | 2020-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $149.55 | 2025 | Compliance Endokit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.42 | 2022-2025 | Xifaxan |
| Covidien LP | $113.26 | 2019 | |
| Janssen Scientific Affairs, LLC | $104.99 | 2020 | |
| Intercept Pharmaceuticals, INC. | $83.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $76.52 | 2022 | |
| Celgene Corporation | $62.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.88 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $41.72 | 2022 | |
| Braintree Laboratories, INC. | $34.42 | 2021-2022 | |
| Pfizer INC. | $31.85 | 2024-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.53 | 2019 | |
| Gilead Sciences, INC. | $19.07 | 2025 | |
| Ardelyx, INC. | $17.35 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Paradowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.